MedeliX
Start asking

Teriparatide

Forsteo, Teriparatide Sun · ATC code H05AA02

Also known as: Teriparatid, Tériparatide, Teriparatida · Brand names: Forsteo, Teriparatide Sun, Osteoteri, Teriparatid Ambio Pharma, Teriparatid Aristo, Teriparatid Beta, Teriparatid Biogaran, Teriparatid Heumann, Teriparatid Ratiopharm, Tetridar, Teriparatid +pharma, Teriparatid Cipla, Tericent

Key facts
Active substance
Teriparatide
ATC code
H05AA02
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
FORSTEO 20 micrograms/80 microliters solution for injection in pre-filled pen · Teriparatide SUN 20 micrograms/80 microliters solution for injection in pre-filled pen
Marketing authorisation holder
Eli Lilly Nederland B.V., Sun Pharmaceutical Industries Europe B.V.
Information as of
2026-10-27

Key facts

Teriparatide is a recombinant fragment of parathyroid hormone with bone-building action (Forsteo, Teriparatide SUN). It is used in adults with osteoporosis at increased risk of fracture.

What it is used for

  • Osteoporosis in postmenopausal women and in men at increased risk of fracture
  • Osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased fracture risk
  • In postmenopausal women, reduction of vertebral and non-vertebral but not hip fractures has been shown

Dosing

  • 20 micrograms once daily by subcutaneous injection in the thigh or abdomen
  • Maximum total treatment duration 24 months; the course is not repeated over a lifetime
  • Supplemental calcium and vitamin D if dietary intake is inadequate
  • Moderate renal impairment and hepatic impairment: caution; no age-based adjustment
  • Other osteoporosis therapies may follow

Contraindications

  • Hypersensitivity, pregnancy and breast-feeding
  • Pre-existing hypercalcaemia, severe renal impairment
  • Other metabolic bone diseases (e.g., hyperparathyroidism, Paget's disease), unexplained raised alkaline phosphatase
  • Prior radiation therapy to the skeleton; skeletal malignancies or bone metastases

Important warnings

  • Transient rise in serum calcium; take calcium samples at least 16 hours after the last injection
  • Caution in active or recent urolithiasis
  • Orthostatic hypotension may occur
  • Not for children or young adults with open epiphyses

Side effects

  • Most common: nausea, pain in limb, headache, dizziness
  • Common: anaemia, hypercholesterolaemia, depression, palpitations, hypotension, dyspnoea
  • Uncommon: hypercalcaemia, tachycardia; rare anaphylaxis

Interactions

  • Digitalis: caution, as transient hypercalcaemia may predispose to digitalis toxicity
  • No clinically significant interactions with hydrochlorothiazide, raloxifene or hormone replacement therapy

Pregnancy and breastfeeding

  • Contraindicated in pregnancy and breast-feeding
  • Women of childbearing potential: effective contraception; discontinue if pregnancy occurs

Summary of the official product information, written with AI on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • ForsteoEli Lilly Nederland B.V. · EMEA/H/C/000425
  • Kauliv · biosimilarStrides Pharma (Cyprus) Limited · EMEA/H/C/004932
  • Livogiva · biosimilarTheramex Ireland Limited · EMEA/H/C/005087
  • Movymia · biosimilarSTADA Arzneimittel AG · EMEA/H/C/004368
  • Sondelbay · biosimilarAccord Healthcare S.L.U. · EMEA/H/C/005827
  • Teriparatide SunSun Pharmaceutical Industries Europe B.V. · EMEA/H/C/005793
  • Terrosa · biosimilarGedeon Richter Plc. · EMEA/H/C/003916
  • Zandoriah · biosimilarCinnaGen Co Unipessoal LDA · EMEA/H/C/006688

Source: European Medicines Agency (EMA), product information

Germany

  • OsteoteriGp-Pharm S.A. · 1 register entry
  • Teriparatid Ambio PharmaAmbio Pharma Europe Limited · 1 register entry
  • Teriparatid AristoAristo Pharma Gmbh (Art 57) · 1 register entry
  • Teriparatid BetaBetapharm Arzneimittel Gmbh · 1 register entry
  • Teriparatid BiogaranBiogaran · 1 register entry
  • Teriparatid HeumannHeumann Pharma Gmbh & Co. Generica Kg · 1 register entry
  • Teriparatid RatiopharmRatiopharm Gmbh · 2 register entries
  • TetridarRatiopharm Gmbh · 2 register entries

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28

Austria

  • Teriparatid +pharma+pharma Arzneimittel Gmbh · 1 register entry
  • Teriparatid CiplaCipla Europe Nv · 1 register entry
  • Teriparatid RatiopharmTeva B.V · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28

Turkey

  • ForsteoLİLLY İLAÇ TİC. LTD. ŞTİ. · 1 register entry
  • TericentCENTURİON İLAÇ SAN. VE TİC. A.Ş. · 2 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 17 more European countries
Bulgaria
Osteoteri
Croatia
Teriparatid Pliva
Cyprus
Bonamens
Denmark
Tetridar
France
Teriparatide Ambio Pharma, Teriparatide Biogaran, Teriparatide Cipla, Teriparatide Teva
Greece
Bonamens, Osteorel
Hungary
Osteoteri, Teriparatid Teva
Iceland
Forsteo, Kauliv, Livogiva, Movymia, Sondelbay, Teriparatide Sun, Terrosa, Zandoriah
Ireland
Teriparatide Cipla, Tetridar
Italy
Oseffyl, Patride, Teriparatide Ambio Pharma, Teriparatide Cipla, Teriparatide Teva
Liechtenstein
Forsteo, Kauliv, Livogiva, Movymia, Sondelbay, Terrosa, Zandoriah
Netherlands
Teriparatide Ambio Pharma, Teriparatide Aristo, Teriparatide Cipla, Teriparatide Teva
Norway
Forsteo, Kauliv, Livogiva, Movymia, Sondelbay, Teriparatide Ambio Pharma, Teriparatide Cipla, Teriparatide Sun, Terrosa, Zandoriah
Poland
Osteoteri
Portugal
Teriparatida Ratiopharm
Spain
Duratil, Osdy, Tetridar
Sweden
Teriparatide Ambio Pharma, Teriparatide Teva

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Forsteo – EPAR, Product Information. 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/forsteo-epar-product-information_en.pdf
  2. European Medicines Agency. Teriparatide Sun – EPAR, Product Information. 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/teriparatide-sun-epar-product-information_en.pdf
  3. EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  4. EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  5. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.